BACKGROUND: The genetic etiologies of the hyper-IgE syndromes are diverse. Approximately 60% to 70% of patients with hyper-IgE syndrome have dominant mutations in STAT3, and a single patient was reported to have a homozygous TYK2 mutation. In the remaining patients with hyper-IgE syndrome, the genetic etiology has not yet been identified. OBJECTIVES: We aimed to identify a gene that is mutated or deleted in autosomal recessive hyper-IgE syndrome. METHODS: We performed genome-wide single nucleotide polymorphism analysis for 9 patients with autosomal-recessive hyper-IgE syndrome to locate copy number variations and homozygous haplotypes. Homozygosity mapping was performed with 12 patients from 7 additional families. The candidate gene was analyzed by genomic and cDNA sequencing to identify causative alleles in a total of 27 patients with autosomal-recessive hyper-IgE syndrome. RESULTS: Subtelomeric biallelic microdeletions were identified in 5 patients at the terminus of chromosome 9p. In all 5 patients, the deleted interval involved dedicator of cytokinesis 8 (DOCK8), encoding a protein implicated in the regulation of the actin cytoskeleton. Sequencing of patients without large deletions revealed 16 patients from 9 unrelated families with distinct homozygous mutations in DOCK8 causing premature termination, frameshift, splice site disruption, and single exon deletions and microdeletions. DOCK8 deficiency was associated with impaired activation of CD4+ and CD8+T cells. CONCLUSION: Autosomal-recessive mutations in DOCK8 are responsible for many, although not all, cases of autosomal-recessive hyper-IgE syndrome. DOCK8 disruption is associated with a phenotype of severe cellular immunodeficiency characterized by susceptibility to viral infections, atopic eczema, defective T-cell activation and T(h)17 cell differentiation, and impaired eosinophil homeostasis and dysregulation of IgE.
BACKGROUND: The genetic etiologies of the hyper-IgE syndromes are diverse. Approximately 60% to 70% of patients with hyper-IgE syndrome have dominant mutations in STAT3, and a single patient was reported to have a homozygous TYK2 mutation. In the remaining patients with hyper-IgE syndrome, the genetic etiology has not yet been identified. OBJECTIVES: We aimed to identify a gene that is mutated or deleted in autosomal recessive hyper-IgE syndrome. METHODS: We performed genome-wide single nucleotide polymorphism analysis for 9 patients with autosomal-recessive hyper-IgE syndrome to locate copy number variations and homozygous haplotypes. Homozygosity mapping was performed with 12 patients from 7 additional families. The candidate gene was analyzed by genomic and cDNA sequencing to identify causative alleles in a total of 27 patients with autosomal-recessive hyper-IgE syndrome. RESULTS: Subtelomeric biallelic microdeletions were identified in 5 patients at the terminus of chromosome 9p. In all 5 patients, the deleted interval involved dedicator of cytokinesis 8 (DOCK8), encoding a protein implicated in the regulation of the actin cytoskeleton. Sequencing of patients without large deletions revealed 16 patients from 9 unrelated families with distinct homozygous mutations in DOCK8 causing premature termination, frameshift, splice site disruption, and single exon deletions and microdeletions. DOCK8 deficiency was associated with impaired activation of CD4+ and CD8+T cells. CONCLUSION: Autosomal-recessive mutations in DOCK8 are responsible for many, although not all, cases of autosomal-recessive hyper-IgE syndrome. DOCK8 disruption is associated with a phenotype of severe cellular immunodeficiency characterized by susceptibility to viral infections, atopic eczema, defective T-cell activation and T(h)17 cell differentiation, and impaired eosinophil homeostasis and dysregulation of IgE.
Authors: Cristina Woellner; Alejandro A Schäffer; Jennifer M Puck; Eleonore D Renner; Constanze Knebel; Steve M Holland; Alessandro Plebani; Bodo Grimbacher Journal: Immunity Date: 2007-05 Impact factor: 31.745
Authors: Svetlana A Yatsenko; Ellen K Brundage; Erin K Roney; Sau Wai Cheung; A Craig Chinault; James R Lupski Journal: Hum Mol Genet Date: 2009-03-17 Impact factor: 6.150
Authors: Lawrence R Shiow; David W Roadcap; Kenneth Paris; Susan R Watson; Irina L Grigorova; Tonya Lebet; Jinping An; Ying Xu; Craig N Jenne; Niko Föger; Ricardo U Sorensen; Christopher C Goodnow; James E Bear; Jennifer M Puck; Jason G Cyster Journal: Nat Immunol Date: 2008-10-05 Impact factor: 25.606
Authors: Theo S Plantinga; Melissa D Johnson; William K Scott; Leo A B Joosten; Jos W M van der Meer; John R Perfect; Bart Jan Kullberg; Mihai G Netea Journal: Med Mycol Date: 2012-06-04 Impact factor: 4.076
Authors: Emily Y Chu; Alexandra F Freeman; Huie Jing; Edward W Cowen; Joie Davis; Helen C Su; Steven M Holland; Maria L Chanco Turner Journal: Arch Dermatol Date: 2011-09-19
Authors: Sara S Kilic; Mustafa Hacimustafaoglu; Stéphanie Boisson-Dupuis; Alexandra Y Kreins; Audrey V Grant; Laurent Abel; Jean-Laurent Casanova Journal: J Pediatr Date: 2012-03-07 Impact factor: 4.406
Authors: Melissa C Mizesko; Pinaki P Banerjee; Linda Monaco-Shawver; Emily M Mace; William E Bernal; Julie Sawalle-Belohradsky; Bernd H Belohradsky; Valerie Heinz; Alexandra F Freeman; Kathleen E Sullivan; Steven M Holland; Troy R Torgerson; Waleed Al-Herz; Janet Chou; Imelda C Hanson; Michael H Albert; Raif S Geha; Ellen D Renner; Jordan S Orange Journal: J Allergy Clin Immunol Date: 2013-02-04 Impact factor: 10.793
Authors: Yu Zhang; Xiaomin Yu; Mie Ichikawa; Jonathan J Lyons; Shrimati Datta; Ian T Lamborn; Huie Jing; Emily S Kim; Matthew Biancalana; Lynne A Wolfe; Thomas DiMaggio; Helen F Matthews; Sarah M Kranick; Kelly D Stone; Steven M Holland; Daniel S Reich; Jason D Hughes; Huseyin Mehmet; Joshua McElwee; Alexandra F Freeman; Hudson H Freeze; Helen C Su; Joshua D Milner Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793